Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study

Krishna Mohan Vadrevu, Siddharth Reddy, Harsh Jogdand, Brunda Ganneru, Nizam Mirza, Virendra Nath Tripathy, Chandramani Singh, Vasant Khalatkar, Siddaiah Prasanth, Sanjay Rai, Raches Ella, William Blackwelder, Sai Prasad, Krishna Ella

Summary

Background Despite having milder symptoms than adults, children are still susceptible to and can transmit SARS-CoV-2. Vaccination across all age groups is therefore necessary to curtail the pandemic. Among the available COVID-19 vaccine platforms, an inactivated vaccine platform has the advantage of excellent safety profile across all age groups; hence, we conducted an age-de-escalation study to assess the safety, reactogenicity, and immunogenicity of an inactivated COVID-19 vaccine, BBV152 (COVAXIN; Bharat Biotech International, Hyderabad, India), in children aged 2–18 years.

Methods In this phase 2/3 open-label, non-randomised, multicentre study done in six hospitals in India, healthy children (male or female) aged 2–18 years were eligible for inclusion into the study. Children who had positive SARS-CoV-2 nucleic acid and serology tests at baseline, or any history of previous SARS-CoV-2 infection, or with known immunosuppressive condition were excluded. Children were sequentially enrolled into one of three groups (>12 to ≤18 years [group 1], >6 to 12 years [group 2], or ≥2 to 6 years [group 3]) and administered with adult formulation of BBV152 as two 0·5 mL intramuscular doses on days 0 and 28. Co-primary endpoints were solicited adverse events for 7 days post-vaccination and neutralising antibody titres on day 56, 28 days after the second dose. Immunogenicity endpoints were compared with Biodefense and Emerging Infections, Research Resources Repository (BEI) reference serum samples and from adults who received two doses of BBV152 in the same schedule in a previously reported phase 2 study. The trial is registered with the Clinical Trials Registry, India (CTR/2021/05/033752) and ClinicalTrials.gov (NCT04918797).

Findings From May 27, 2021, to July 10, 2021, we enrolled 526 children sequentially into groups 1 (n=176), 2 (n=175), and 3 (n=175). Vaccination was well tolerated, with no differences in reactogenicity between the three age groups, and no serious adverse events, deaths, or withdrawals due to an adverse event. Local reactions mainly consisted of mild injection site pain in 46 (26%) of 176 participants in group 1, 61 (35%) of 175 in group 2, and 39 (22%) of 175 in group 3 after dose 1; and 39 (22%) of 175 in group 1, 43 of 175 (25%) in group 2, and 14 of 175 (8%) in group 3 after dose 2; there were no cases of severe pain and few reports of other local reactions. After dose 1, the most frequent solicited systemic adverse event was mild-to-moderate fever, reported in eight (5%) of 176 participants in group 1, 17 (10%) of 175 in group 2, and 22 (13%) of 175 in group 3. No case of severe fever was reported, and rates of all fever were all 4% or less after dose 2. Geometric mean titres (GMTs) of microneutralisation antibodies at day 56 in groups 1 (138·8 [95% CI 111·0–173·6]), 2 (137·4 [99·1–167·5]), and 3 (197·6 [176·4–221·4]) were similar to titres in vaccinated adults (160·1 [135·8–188·8]) and with BEI reference serum samples (103·3 [50·3–202·1]). Similar results were obtained using the plaque reduction neutralisation test (PRNT), in which 166 (95%) of 175 participants in group 1, 165 (98%) of 165 in group 2, and 169 (98%) of 172 in group 3 seroconverted at day 56. The GMT ratio of PRNT titres in children and adults was 1·76 (95% CI 1·32–2·33), indicating a superior response in children compared with adults.

Interpretation BBV152 was well tolerated in children aged 2–18 years, and induced higher neutralising antibody responses than those observed in adults, in whom the efficacy (ie, the prevention or decrease in the severity of COVID-19 infection) has been demonstrated.

Funding Bharat Biotech International.

Copyright © 2022 Elsevier Ltd. All rights reserved.

Introduction

There is an ongoing global inequality in the distribution of effective vaccines against SARS-CoV-2 with some low-income and middle-income countries unable to either afford the most widely used vaccines, or provide the necessary infrastructure to store and distribute the vaccines that require storage at –20°C. To meet this need, a whole-virion adjuvanted inactivated SARS-CoV-2 vaccine

**Lancet Infect Dis 2022; 22: 1303–12**

Published Online June 16, 2022
https://doi.org/10.1016/S1473-3099(22)00310-3

See Comment page 1255

Bharat Biotech, Hyderabad, India (K M Vadrevu PhD, S Reddy MSc, H Jogdand DVM, B Ganneru PhD, S Prasad MBA, K Ella PhD); Pranaam Hospital, Hyderabad, Telangana, India (N Mirza MBBS); Prakhar Hospital, Kanpur, India (V N Tripathy MBBS); All India Institute of Medical Sciences, Patna, India (C Singh MBBS); Meditina Institute of Medical Sciences, Nagpur, Maharashtra, India (V Khalatkar MBBS); Cheluvamba Hospital, Mysore, Karnataka, India (S Prasanth MBBS); All India Institute of Medical Sciences, New Delhi, India (S Rai MBBS); Independent Consultant, Cambridge, Massachusetts, USA (R Ella PhD); WB Statistical Consulting, Bethesda, Maryland, USA (W Blackwelder PhD)

Correspondence to: Dr Krishna Mohan Vadrevu, Bharat Biotech, Genome Valley, Hyderabad 500 078, India kmohan@bharatbiotech.com
Research in context

Evidence before this study
COVID-19 vaccination efforts to date have focused on the adult and older populations that constituted those with the most serious outcomes; therefore, vaccine studies also focused on these groups. We searched PubMed on April 2, 2022, for research articles using the search terms “SARS-CoV-2”, “COVID-19”, “vaccine”, “paediatric”, and “children”, with no language or date restrictions. We found several publications on COVID-19 vaccine clinical trials in children and adolescents, mainly with mRNA vaccines, to investigate their safety and reactogenicity and immune responses. Clinical trial results from two other inactivated vaccines reported humoral responses but minimal cell-mediated responses. From our published phase 3 data, we have shown that two doses of BBV152, a Vero cell-based whole-virion inactivated SARS-CoV-2 vaccine, elicits 78% efficacy against RT-PCR-confirmed COVID-19 and 65.2% against PCR-confirmed COVID-19 caused by the delta variant in adults. The low reactogenicity of this vaccine in adults make it an ideal candidate for the extension of vaccination to younger age groups.

Added value of this study
To our knowledge, this study is the first on the immunogenicity and safety of the BBV152 vaccine in children aged 2–18 years. Our preliminary analyses show the vaccine was well tolerated with no serious adverse events, deaths, or withdrawals due to an adverse event reported during the study. This finding is consistent with the larger dataset available from several studies with the vaccine in adults. BBV152 induced immune responses in children that were equivalent or superior to those previously demonstrated in adults in whom the vaccine has demonstrated protective efficacy. This finding suggest that BBV152 might be equally efficacious in protecting children against severe COVID-19. Because BBV152 is an inactivated vaccine, it is unlikely to lead to adverse events that have implied to be associated with paediatric vaccination with mRNA vaccines such as cases of Guillain-Barré syndrome, thromboembolic events, or myocarditis or pericarditis.

Implications of all the available evidence
Our findings with BBV152 are in accordance with humoral immune responses reported for other inactivated SARS-CoV-2 vaccine candidates and support extension of its use from adults to adolescents and children to broaden vaccine-induced immunity against SARS-CoV-2. Inclusion of younger age groups will help to interrupt transmission of the virus and diminish outbreaks. The low reactogenicity might make the vaccine more acceptable in paediatric populations than the more reactogenic mRNA vaccines, and as BBV152 can be stored at 2–8°C, it is compatible with immunisation cold chain requirements for many developing countries, where it will be a valuable tool in the global immunisation effort. Follow-up studies to assess paediatric effectiveness are underway, but our study suggests that similar efficacy might be anticipated in children based on the observation of superior immunogenicity than in adults.

(BBV152 [COVAXIN]: Bharat Biotech International, Hyderabad, India) was developed that can be stored at standard refrigerator temperatures (2–8°C). A 2021 trial involving more than 25 000 adults demonstrated that two doses of BBV152 have 77.8% (95% CI 65.2–86.4) efficacy against RT-PCR-confirmed COVID-19 of any severity. A smaller study, in 3732 Indian health-care workers in conditions of high infectious pressure during the second wave of COVID-19 (probably of the B.1.617.2 [delta] variant), found 46–57% efficacy against symptomatic PCR-confirmed SARS-CoV-2 infection depending on the vaccination interval.

Paediatric COVID-19 infections have not been associated with the high rates of morbidity and mortality observed in older adults, and paediatric deaths are rare. Children have been shown to be equally at risk of infection as adults although such infections tend to be asymptomatic, and might be a source of the ongoing infections in more susceptible populations. Moreover, the increasing occurrence of variants of concern has been associated with an increasing proportion of infections in children. This increase has led several countries, including the US Centers for Disease Control and Prevention (CDC) and European Medicines Agency (EMA), to extend licensure of current adult mRNA vaccines to include children older than 5 years, making the development of effective vaccines or the establishment of current vaccines as being suitable for use in children a medical priority, both to protect this population and to increase herd immunity. To meet this need, we assessed the safety and immunogenicity of BBV152 in an open-label, age de-escalation study in three cohorts of children aged between 2 years and 18 years.

Methods
Study design and participants
This was a phase 2/3 open-label, non-randomised, multicentre study done across six hospitals in India. Eligible participants were healthy children (male or female), aged 2–18 years. The trial was conducted in compliance with all International Council for Harmonisation Good Clinical Practice guidelines. The trial was approved by the National Regulatory Authority (Central Drugs Standard Control Organization, India) and also by the respective hospital ethics committees (Pranam Hospital, Hyderabad; All India Institute of Medical Sciences [AIIMS], Patna; Prakash Hospital, Kanpur; Cheluvambha Hospital, Mysore; Meditrina Institute of Medical Sciences, Nagpur and AIIMS, New Delhi; appendix p 2). The protocol is registered with the
Inclusion criteria included general good health in the investigator’s opinion, ability to fulfill the study criteria, residence in the study area for its duration, and no participation in any other clinical trial. The main exclusion criteria were any history of previous COVID-19 vaccination, SARS-CoV-2 infection confirmed by RT-PCR or ELISA at screening, a temperature (>38.0°C) or symptoms of an acute illness within 3 days of a vaccination, known sensitivity to any vaccine component, receipt of any other vaccine within 4 weeks of the study or any known immunosuppressive condition or treatment likely to interfere with the immune response. Children were excluded from receiving a second dose, if they displayed any anaphylactic reaction to the first vaccination or had a virologically confirmed SARS-CoV-2 infection between doses.

Parents or legal guardians of all participants supplied written informed and audio–visual consent; verbal assent was also obtained from children aged 7–12 years, and written consent from children older than 12 years to 18 years.

Procedures
The vaccine antigen is a β-propiolactone-inactivated whole virion of SARS-CoV-2 vaccine strain NIV-2020-770 (GISAID; GenBank accession number EPL_ISL_420545), isolated from an Italian tourist taken ill while making a visit to New Delhi, India, and sequenced at the Indian Council of Medical Research National Institute of Virology (Pune, India).12 Each 0.5 mL dose of BBV152 contains 6 µg antigen with a toll-like receptor 7/8 agonist molecule (imidazoquinoline; IMDG) adsorbed to alum (Algel-IMDG). The vaccine was supplied in glass vials, stored at 2–8°C, for administration by intramuscular injection in the upper deltoid of the non-dominant arm (usually the left arm) in a two-dose regimen on days 0 and 28.

Age de-escalation was done by recruiting three age groups in sequence, beginning with the oldest group: group 1, older than 12 years to 18 years. A small number of participants were initially recruited to group 1 and received their first vaccination. The data safety monitoring board then assessed 7 days of safety and reactogenicity data before giving approval to recruit and vaccinate the remaining participants in that age group. Only after completion of the group 1 vaccination was the data safety monitoring board approval process initiated with children older than 6 years to 12 years (group 2), again in a small initial cohort before recruiting all participants, and then this was repeated with the youngest children in group 3, aged at least 2 years to 6 years.

All children were screened for SARS-CoV-2 infection by RT-PCR (appendix pp 11–12) and antibody detection assay (ELISA/CLIA; appendix pp 13–15) on day 0, when eligible participants had a general physical examination and assessment for potential SARS-CoV-2 infection. They were then vaccinated, and after administration of each dose, the participant was monitored for 2 h for immediate reactions. Parents or guardians were trained on how to complete study diaries for 7 days in which solicited local reactions (pain, redness, swelling, stiffness, and tenderness at the injection site) and systemic adverse events (body pain, fatigue, headache, loss of appetite, nausea, vomiting, pain in extremities, arthralgia, weakness, and fever), which were graded by the parents for severity as mild, moderate, or severe.

Active surveillance of reactogenicity and possible SARS-CoV-2 infection was also done during these 7 days by telephone contact with the parents or guardians who were also instructed to record any occurrence of a serious adverse event or adverse event of special interest and to report the event immediately to the investigator. Blood was drawn on days 0, 28 (before dosing), and 56 (4 weeks, post second dose), to assess immune responses.

Serum samples were separated immediately after the blood collection and stored at −20°C for measurement of immune responses (appendix pp 15–17). SARS-CoV-2 virus neutralising antibodies were measured using micro-neutralisation (MNT) and plaque reduction neutralisation (PRNT) tests, with titres expressed as reciprocal of the serum sample dilution achieving 50% neutralisation (MNTₜₕ or PRNTₜₕ). Because there is no established correlate of protection against COVID-19, vaccine-induced responses were compared with a panel of 18 internationally recognised reference serum samples (Biodefense and Emerging Infections, Research Resources Repository [BEI], NIAID, NIH). IgG antibody titres against SARS-CoV-2 S-protein, receptor-binding domain (RBD), and nucleocapsid protein (N-protein) were measured by ELISA and expressed as the reciprocal of the highest serum sample dilution showing binding to antigen.

Outcomes
The co-primary immunogenicity objective was measured as the geometric mean titres (GMTs) and seroconversion rates of neutralising antibodies elicited by vaccination in each age group. As there was no internal control these values in children were compared with the same measurements done in an adult population from a previously reported phase 2 study with a similar design. This interim report presents data obtained up to 4 weeks after the second dose, but the study is ongoing to collect data up to 6 months after the last vaccination, which will be reported separately.

Post-hoc analysis using subset of samples (15 from each age group) was performed to evaluate the capacity of vaccine-induced antibodies to block the interaction between human ACE-2 receptor and the RBD from the
wild-type SARS-CoV-2 strain (D614G), and the delta (B.1.617.2) and omicron (B.1.1.529) variants with a surrogate virus neutralisation test (sVNT). 14,15 Similarly, another post-hoc analysis of randomly selected serum samples (n=24) was done to measure IgG1:IgG4 ratios as an indicator of the Th1/Th2 responses.13,16

The outcomes for the primary safety and reactogenicity objectives were the assessments of the occurrence of solicited adverse events and their severity within 7 days after the administration of each dose, and unsolicited adverse events, serious adverse events, and adverse event of special interest throughout the study.

Statistical analysis

The sample size was intended to allow separate comparisons of GMTs at day 56 between each of the three age groups, and against titres observed in adults in an earlier phase 2 study.13 Per-protocol non-inferiority analyses were based on those who received two doses of vaccine. Paediatric age groups were considered non-inferior to the adult group if the 95% CI for GMT ratio (paediatric group GMT /adult GMT) had a lower limit of at least 0·5 (non-inferiority margin). Based on the phase 2 trial data, we assumed the SD of log10 (titre) to be 0·8 for each paediatric group, such that the true underlying GMT is lower in the paediatric subgroup. Using a t-test for non-inferiority on the difference in means of log10 (titre) with assumed true difference of log10(0·8) of –0·096910 and non-inferiority margin of log10(0·5) of –0·30103. The power to show non-inferiority for a single paediatric age subgroup is approximately 0·95615 (PASS 2020, NCSS, Kaysville, Utah, USA).
Solicited local reactions

- Pain
- Redness
- Stiffness
- Swelling
- Tenderness

Solicited systemic adverse events

- Dose 1
  - Pain
  - Redness
  - Stiffness
  - Swelling
  - Tenderness

- Dose 2
  - Pain
  - Redness
  - Stiffness
  - Swelling
  - Tenderness

Severity of adverse event
- Mild
- Moderate

Participants reporting adverse event (%)
probability that the non-inferiority criterion would be met for all three paediatric age subgroups is approximately \( (0.95615^3) \), or approximately 87%. We assumed sample sizes of 150 individuals providing data for each paediatric subgroup and 177 for the adult group, which is the number reported from the phase 2 trial with titre data at day 56. To allow for loss of data due to withdrawals and loss to follow-up, we planned to enrol 175 children into each of the three paediatric age subgroups.

GMTs were calculated for neutralisation antibodies and ELISA IgG antibodies for each age group separately. A two-sided 95% CI for the post-vaccination GMT was calculated from a 95% CI for the mean of log-transformed titre, using a normal approximation for the distribution of log (titre). For each age group, the ratio of GMTs with corresponding 95% CI versus the adult group are presented. The 95% CI for the GMT ratio was calculated from a 95% CI for the difference in means of \( \log_{10} \) (titre).

Groups were compared using a two-sided two sample t-test on the means of log-transformed titres. The primary comparison was the GMT ratios after the second dose. Secondary post-hoc comparisons were done with earlier reported data obtained 4 weeks after the second dose in initially seronegative adults in a phase 2 study. Seroconversion rates were calculated as group proportions achieving a four-times increase in titre from baseline (day 0) to days 28 or 56 with two-sided 95% CIs. For differences between seroconversion rates, exact 95% CIs were calculated and seroconversion rates compared using two-sided Fisher exact tests, with the p value obtained by doubling the smaller of the one-sided p values. All statistical analyses were done using SAS (version 9.4), R (version 4.1.2), and GraphPad Prism (version 9.0.2 [161]). A p value less than 0.05 was considered significant.

Role of the funding source

The sponsor of the study had no role in data collection, data analysis, data interpretation, or writing the report. A contract research organisation (Sclin Soft Technologies, Hyderabad, India) was responsible for data analysis and generating the report. The unblinded contract research organisation and several authors from Bharat Biotech had full access to the data in the study. Authors from Bharat Biotech had final responsibility for the decision to submit for publication.

Results

From May 26, to July 10, 2021, we screened 976 potential participants sequentially (group 1 n=334; group 2 n=320; group 3 n=322); of the people screened, 342 (group 1 n=98, group 2 n=116, and group 3 n=128) were excluded for seropositivity for SARS-CoV-2 infection according to RT-PCR or ELISA testing (figure 1). Of the 634 eligible children, 526 were enrolled to complete the required study size and these children were vaccinated (group 1 n=176, group 2=175, and group 3 n=175). One child in group 1 did not receive a second dose after being diagnosed with COVID-19 on day 15. There were more males than females in each age group, and this difference was largest in the group 3 (table 1).

There were no serious adverse events, deaths, or withdrawals due to an adverse event during the study, with the exception of one case of COVID-19 in group 1. No cases of Guillain-Barré syndrome, thromboembolic events, myocarditis or pericarditis, or other adverse event of special interest have been reported to date. Vaccination with BBV152 was generally well tolerated, with mild-to-moderate reactogenicity profiles (figure 2). There were no differences in these profiles between
Local reactions mainly consisted of mild injection site pain, reported by less than 35% of any group after the first dose (46 of 176 in group 1, 61 of 175 in group 2, and 39 of 175 in group 3), and less than 25% after the second dose (39 of 176 in group 1, 43 of 175 in group 2, and 14 of 175 in group 3); there were no cases of severe pain. There were few reports of other local reactions. Systemic adverse events were less frequent, especially after the second dose. After dose 1, the most frequent systemic adverse event was mild-to-moderate fever, reported in eight (5%) of 176 group 1 participants, 17 (10%) of 175 group 2 participants, and 22 (13%) of 175 of children in group 3. No case of severe fever was reported and rates of all fever were all 4% or less after dose 2.

Unsolicited adverse events were also infrequent after vaccination, reported for three (2%) of 176 children in group 1, eight (5%) of 175 children in group 2, and four (2%) of 175 children in group 3. All unsolicited adverse events, which consisted of individual reports of typical childhood complaints likely to occur independent of vaccination (appendix p 3), were described as mild and resolved without sequelae.

Table 2: Neutralising antibody titres

| Group    | Group 1 | Group 2 | Group 3 | Adults† |
|----------|---------|---------|---------|---------|
| **MNT<sub>50</sub>** |         |         |         |         |
| Day 0    |         |         |         |         |
| n        | 175     | 175     | 175     | NA      |
| GMT      | 10·1 (8·9–11·5) | 8·5 (7·8–9·3) | 5·8 (5·7–5·9) | NA      |
| Day 28   |         |         |         |         |
| n        | 175     | 175     | 175     | NA      |
| GMT      | 21·9 (17·8–27·1) | 31·8 (24·9–40·6) | 14·8 (13·7–16·0) | NA      |
| Seroconverted* | 44 (25%; 19·3–32·1) | 70 (45%; 37·0–52·4) | 26 (15%; 10·3–20·9) | NA      |
| Day 56   |         |         |         |         |
| n        | 175     | 175     | 173     | 177     |
| GMT      | 138·8 (111·0–173·6) | 137·4 (99·1–167·5) | 197·6 (176·4–221·4) | 160·1 (135·8–188·8) |
| GMTR (group vs adults) | 0·87 (0·66–1·14) | 0·86 (0·64–1·16) | 1·23 (1·01–1·51) | 0·98 (0·80–1·19)† |
| Seroconverted* | 158 (90%; 84·9–94·2) | 141 (90%; 84·0–94·1) | 173 (100%; 97·9–100) | 171 (97%; 92·8–98·7) |
| p value vs adult | <0·05 | <0·05 | <0·05 | NA      |

| **PRNT<sub>50</sub>** |         |         |         |         |
| Day 0    |         |         |         |         |
| n        | 175     | 175     | 175     | NA      |
| GMT      | 0·20 (0·14–0·27) | 0·11 (0·09–0·14) | 0·15 (0·12–0·18) | NA      |
| Day 28   |         |         |         |         |
| n        | 175     | 175     | 175     | NA      |
| GMT      | 11·2 (7·0–17·9) | 13·5 (9·3–19·6) | 9·1 (6·1–12·5) | NA      |
| Seroconverted* | 111 (63%; 56·1–70·2) | 143 (82%; 75·3–86·8) | 126 (72%; 64·3–77·6) | NA      |
| Day 56   |         |         |         |         |
| n        | 175     | 175     | 172     | 177     |
| GMT      | 327·4 (224·4–449·2) | 366·9 (297·0–453·3) | 358·6 (287·2–447·8) | 197·0 (155·6–249·4) |
| GMTR (group vs adults) | 1·61 (1·05–2·43) | 1·86 (1·35–2·55) | 1·82 (1·31–2·51) | 1·76 (1·32–2·33)† |
| Seroconverted* | 166 (95%, 90·5–97·6) | 165 (98%, 94·9–99·6) | 169 (98%, 95·0–99·6) | 174 (98%, 95·1–99·6) |
| p value vs adult | ns | ns | ns | NA      |

MNT<sub>50</sub> = microneutralisation test. NA = not applicable. GMT = geometric mean titre. GMTR = geometric mean titre ratio. PRNT<sub>50</sub> = plaque reduction neutralisation test.

†Seroconversion defined as a four-times increase in titre over baseline at day 0. GMTR for neutralising antibodies measured by MNT or PRNT between paediatric groups 1, 2, and 3 in this study and adults in phase 2 study. Thus, a paediatric age subgroup was considered non-inferior to the adult group if the 95% CI for GMTR (GMT in a paediatric subgroup/GMT in adults) had a lower limit of at least 0·5. The PRNT GMTR (GMT in a paediatric subgroup/GMT in adults) had a lower limit of at least 1, indicating a superior response in children when compared with adults. All children versus adults.

Table 2: Neutralising antibody titres Data are n, GMT (95% CI), GMTR (95% CI), or n (%; 95% CI). GMTs, GMTRs, and seroconversion rates for SARS-CoV-2 neutralising antibodies measured by MNT<sub>50</sub> or plaque PRNT<sub>50</sub> with values from a phase 2 adult study.
(99·1–167·5; group 2). When assessed by PRNT, there was no difference between groups in terms of GMTs or seroconversion rates after two doses (figure 3; table 2). On day 56, the GMT ratio comparing children with adults was 1.76 (95% CI 1.32–2.33). Seroconversion 4 weeks after the second vaccination was high (95–98%) in all three groups, and similar to the phase 2 study in adults. Neutralising GMTs measured by PRNT were higher in all three groups of children (317·4 in group 1, 366·9 in group 2, and 358·6 in group 3) than those previously reported in adults (197·0 [95% CI 155·6–249·4]; table 2).

In an exploratory investigation using the sVNT assay we found that vaccine-induced antibodies were able to block the interaction between human ACE2 and RBD of both D614G and delta variants with low activity against the omicron variant. On day 56, 15 (100%) of 15 participants across all three age groups showed neutralisation against D614G across all age groups, with GMTs of inhibition ranging from 63·6% to 94·4% at 1:10 serum dilution. Neutralisation was age dependent against the delta variant, observed in 12 (80%) of 15 participants in group 1, and 15 (100%) of 15 participants in groups 2 and 3, with GMTs of inhibition of 49·4% in group 1, 84·2% in group 2, and 91·1% in group 3. When tested with neat sera (without dilution) against the omicron variant, four (27%) of 15 participants from groups 2 and 3 demonstrated neutralisation with 1·2–4·7% inhibition, whereas none of the participants in group 1 demonstrated any neutralisation of the omicron variant. Vaccine-induced neutralisation efficiency at day 56 was statistically significant (p<0·0001) compared with neutralisation efficacy at day 0 across all age groups against D614G, and the delta and omicron variants, except in group 1 against omicron (appendix pp 8–9).

Binding IgG antibody responses against the three main antigenic SARS-CoV-2 protein components, S-protein, RBD, and N-protein, are illustrated in figure 4 (appendix pp 4–6); all three age groups responded in a similar manner with similar magnitude against the three proteins except for a lower GMT at day 56 for N-protein in group 3. Isotyping ratios (IgG1/IgG4) at day 56 were above 1 for all vaccinated groups, indicative of a Th1 bias (appendix p 10).

**Discussion**

We previously demonstrated that two doses of BBV152 are effective in preventing COVID-19 due to SARS-CoV-2 infection in adults,2,3 and now show that the vaccine is equally well tolerated and immunogenic in seronegative children aged 2–18 years. No adverse events of special interest have been reported to date; however, a supplementary surveillance study is ongoing, which will provide more information on rarer adverse events. Neutralising antibody responses measured by MNT or PRNT after two doses in a cohort of children aged 2–18 years are non-inferior to those observed in adults. The GMT ratio of neutralising antibodies measured by PRNT in children versus adults had a lower limit of 1 or more, indicating a superior response in children. Although neutralising titres are not a correlate of protection, the fact that this vaccination schedule has been...
shown to protect against infection in adults thus suggests BBV152 might also be efficacious in the paediatric cohort. Furthermore, preliminary assessments show the induced antibodies were able to block the interaction between human ACE2 and RBD from both the wild-type (D614G) and delta variant, whereas the effectiveness against omicron was low. These results suggest the importance of a third dose, to enhance effectiveness against omicron, which has been shown (in a preprint) in adults with BBV15220 and other COVID-19 vaccines.21 Further studies with a third dose of BBV152 in children will be required to confirm any protection against such infections.

A Th1-dominant response has been suggested to be preferable for COVID-19 vaccines;22 we also demonstrated that the immune response towards BBV152 was skewed towards a Th1 response with IgG1/IgG4 ratios above 1.11,13 An earlier study in adults vaccinated with BBV152 reported cross-reactive T-cell responses to several SARS-CoV-2 variants (alpha, beta, and delta).20 The pattern of baseline neutralising antibody GMTs suggests an age-dependent increase (appendix p 7), possibly due to the older children interacting with a greater number of other children socially and thus more likely to be exposed to COVID-19. This study was conducted during the second wave of COVID-19 in India from March to July, 2021, which peaked on May 3.21 The only case of symptomatic COVID-19 detected in the study was in the oldest age group: however, visits to assess severity or duration of disease were not scheduled, and routine SARS-CoV-2 nucleic acid testing was not conducted, so asymptomatic or mild symptomatic cases of COVID-19 might have been missed.

Schoolchildren were not prioritised for global vaccination programmes generally and thus remained vulnerable to SARS-CoV-2 infection.23 With the new emerging variants,24 the number of cases and hospitalisation in children started to increase compared with earlier in the pandemic. Hence, preventing SARS-CoV-2 infection across all age groups, including children, by vaccination will continue to be critical to curtail the pandemic. Vaccination of younger age groups with licensed adult COVID-19 vaccines25 would not only reduce the severity, hospitalisations, and long-term complications of COVID-19, but might also reduce household transmission and severity in vulnerable individuals, including immunocompromised or comorbid individuals.15 The pandemic necessitated regulatory body approval of the use of available safe and effective COVID-19 vaccines in children as a precautionary measure.21

Globally, inactivated vaccines and mRNA vaccines form the majority of COVID-19 vaccines approved for administration to children younger than 18 years. An advantage of this study is the demonstration of acceptable tolerability and significant immunogenicity of BBV152 in children as young as 2 years, supported by a safety profile similar to that in adults. Inactivated COVID-19 vaccines have been shown to be well tolerated and immunogenic in phase 1/2 trials in Chinese children aged 3–17 years.20,26 An advantage of whole-virion vaccines such as BBV152 is that multiple epitopes are present, as illustrated by the marked responses against S-protein, RBD, and N-protein in this study. Furthermore, after a booster (third) dose BBV152 showed (in a preprint) enhanced in vitro neutralisation against variants of concern, including omicron in adults,27 despite inducing only low or moderate neutralising antibody titres compared with mRNA vaccines. Vikkurthi and colleagues, also show (in a preprint) that, ex vivo, BBV152-generated T cells (Tfh) assist in B-cell production of antibodies against SARS-CoV-2 variants of concern.20

Our study was limited by the ethical considerations of doing a study in children, and it was for these reasons that our study was small, open label, and without a placebo group. However, the low rates of reported reactogenicity, except for injection site pain, suggest that a control group would not have revealed any medically significant tolerability issues. Transient mild-to-moderate injection site pain is the main adverse event reported by adults not only with BBV152,21 but also with other COVID-19 vaccines. The small size of the study means that we cannot draw firm conclusions about vaccine safety in children as rare events, eg myocarditis, will only be detected in larger surveillance studies, which are ongoing. Finally, we have assessed only the immunogenicity of BBV152, not clinical efficacy, in children.

In conclusion, the inactivated SARS-CoV-2 vaccine BBV152, was well tolerated and immunogenic in children aged 2–18 years, with neutralising antibody responses at least similar to those observed in adults in whom the vaccine has been proven to be efficacious against symptomatic and asymptomatic COVID-19. This, combined with their ability to be stored stably at warmer (fridge) temperatures than the mRNA30 and vector-based vaccines that have been widely used in high-income countries, make BBV152 an attractive alternative to those vaccines for wider global use. The vaccine has been approved for use by the Indian government in children aged 15–18 years.23 We await further safety data from the large surveillance study in children aged 2 years and older.

**Declaration of interests**

This work was funded by Bharat Biotech International. KMV, SRe, BG, HJ, and SPrasad, are employees of Bharat Biotech, with no stock options.
was funded by Bharat Biotech International Limited. The Netherlands) for editorial assistance with the manuscript. The study could not have been developed without the efforts of the data safety monitoring board and adjudication committee for their continued support and guidance of this ongoing clinical programme. This vaccine candidate could not have been developed without the efforts of Bharat Biotech's manufacturing, and quality control teams. We are grateful to Keith Veitch (Reithveitch Communications, Amsterdam, The Netherlands) for editorial assistance with the manuscript. The study was funded by Bharat Biotech International Limited.

Acknowledgments

We sincerely thank the volunteers, investigators, study coordinators, and health-care workers involved in this study. We express our gratitude to the teams at Scin Soft Technologies for their support with data management. Shashi Kanth Muni, Yuvraj Jogdand, Vinay Kumar Aileni, Jagdish Kumar, Bhargav Reddy, Sandhya Rani, Aparna Bathula, Krishna Shilpa Palern, Raju Dugyala, and Usha Paturi (Bharat Biotech) participated in protocol design and clinical trial monitoring. We also acknowledge the contributions of Ramulu Chintalala, Spandana Sure, Krishna Shilpa Palern, Raju Dugyala, and Usha Paturi (Bharat Biotech) for performing the eVTN assay and ELISA. We thank the members of the data safety monitoring board and adjudication committee for their continued support and guidance of this ongoing clinical programme.

References

1. Crommelin DJA, Anchordogy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the cold reality of mRNA vaccine stability. *J Pharm Sci* 2021; 110: 997–1001.
2. Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. *Lancet Infect Dis* 2021; 21: 637–46.
3. Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. *Lancet* 2021; 398: 2173–84.
4. Desai D, Khan AR, Soneja M, et al. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study. *Lancet Infect Dis* 2022; 22: 349–56.
5. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. *Acta Paediatr* 2020; 109: 1088–95.
6. Ladhani SN, Amin-Chowdhury Z, Davies HG, et al. COVID-19 in children: analysis of the first pandemic peak in England. *Arch Dis Child* 2020; 105: 1180–85.
7. Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis* 2020; 20: 911–19.
8. Otto SP, Day T, Arino J, et al. The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. *Curr Biol* 2021; 31: R918–29.
9. Mahapatra S. COVID become a disease of the young? *Nature* 2021; 595: 143–44.
10. US Food and Drug Administration. FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in children 5 through 11 years of age. 2021. https://www.fda.gov/news-events/press-announcements/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age (accessed May 25, 2022).
11. European Medicines Agency. Comirnaty COVID-19 vaccine: EMA recommends approval for children aged 5 to 11. 2021. https://www.ema.europa.eu/en/news/comirnaty-covid-19-vaccine-ema-recommends-approval-children-aged-5-11 (accessed May 25, 2022).
12. Ganneau B, Jogdand H, Daram VK, et al. Thi skewed immune response of whole virus inactivated SARS-CoV-2 vaccine and its safety evaluation. *Science* 2021; 24: 102298.